Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Algorithm Prediction

Research Leaders

7 sponsors active, led by King's College London

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Recruiting1
Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04663750Phase 3Recruiting

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

NCT05324150CompletedPrimary

M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD

NCT04640649Not ApplicableUnknown

Prediction of Progression of Age-Related Macular Degeneration

Showing all 3 trials

Research Network

Common Treatments

  • Algorithm Prediction1
  • Subretinal Injection Of Recombinant Tpa Alteplase Up To A Maximum Of 25 Micrograms In 02 Mls1
  • Intravitreal 20 Sulfahexafluoride Sf6 Gas Tamponade1
  • Pars Plana Vitrectomy1
  • Intravitreal 2 Mg Aflibercept Will Be Injected At Baseline Then Monthly For Two Further Doses Then 2monthly Until Month 121

Active Sponsors

  • King's College London1
  • King's College Hospital NHS Trust1
  • Ospedale Santa Croce-Carle Cuneo1
  • Illinois Retina Associates1
  • Stanford University1

Top Investigators

Related Conditions

  • Submacular Hemorrhage1
  • Eye Diseases1
  • Metamorphopsia1
  • Macular Degeneration Dry1
  • Macular Degeneration1

Activity Timeline